---
title: "Why Your Newborn Needs a Vitamin K Shot: The Neurology and Hematology"
description: "Understanding vitamin K deficiency bleeding and why the birth dose is standard careâ€”from a pediatric neurology perspective"
publishedAt: "2025-01-22"
updatedAt: "2025-01-22"
author: "Alisha Blevins, MSN, CPNP-PC, Pediatric Neurology NP"
category: "newborn care"
tags: ["newborn", "vitamin K", "VKDB", "neurology", "preventive care"]
ageRanges: ["0-3mo"]
journeyType: "learning"
isSpecialty: false
featured: false
focusKeyword: "vitamin K shot newborn"
---

## Introduction

Within your baby's first hour of life, your healthcare team will recommend a single intramuscular injection of vitamin K. This interventionâ€”standard practice in the United States since 1961â€”prevents a rare but potentially catastrophic condition: Vitamin K Deficiency Bleeding (VKDB).

As a Pediatric Neurology Nurse Practitioner, I encounter the neurological consequences when bleeding disorders affect the developing brain. I've seen infants with intracranial hemorrhageâ€”bleeding inside the skullâ€”that could have been prevented with a single vitamin K dose at birth. These cases are uncommon because vitamin K prophylaxis is widely accepted, but when parents decline the shot, the risk becomes real.

This isn't about fear. It's about understanding the physiology: why newborns are uniquely vulnerable to vitamin K deficiency, what happens when bleeding occurs in critical locations like the brain, and why the intramuscular shot remains the most reliable prevention method.

Understanding vitamin K prophylaxis helps you:

- Recognize why newborns have physiologically low vitamin K stores
- Understand the specific risks of VKDB and its timing
- Evaluate the evidence comparing injection vs. oral administration
- Make an informed decision grounded in clinical data rather than anecdotal concerns

Let's examine the science behind this routineâ€”but criticalâ€”newborn intervention.

---

## Table of Contents

- What Is Vitamin K and Why Does It Matter?
- Why Newborns Are Deficient: The Physiology
- Vitamin K Deficiency Bleeding (VKDB): Types and Timing
- Neurological Consequences: Why the Brain Is at Risk
- The Vitamin K Shot: Dosing and Safety
- Intramuscular vs. Oral: Comparing Effectiveness
- Common Concerns About the Vitamin K Shot
- What Happens If You Decline
- Key Takeaways
- FAQ
- References & Citations

---

## What Is Vitamin K and Why Does It Matter?

### The Role of Vitamin K

Vitamin K is a fat-soluble vitamin essential for synthesizing clotting factorsâ€”proteins that enable blood to clot and stop bleeding. Specifically, vitamin K activates four clotting factors (II, VII, IX, X) and two regulatory proteins (Protein C and Protein S) in the liver.

**Without adequate vitamin K:**

- These clotting factors remain inactive
- Blood cannot clot effectively
- Even minor bleeding can become uncontrolled
- Internal bleeding can occur without obvious external injury

### Vitamin K Sources

Adults obtain vitamin K from two primary sources:

1. **Dietary vitamin K1 (phylloquinone):** Found in leafy greens, vegetable oils, some fruits
2. **Bacterial synthesis of vitamin K2 (menaquinone):** Produced by gut bacteria

Newborns have neither source in adequate amounts.

---

## Why Newborns Are Deficient: The Physiology

Newborns are born with low vitamin K stores due to multiple physiological factors:

### 1. Limited Placental Transfer

Vitamin K crosses the placenta poorly, even when maternal levels are adequate. Cord blood vitamin K concentrations are typically 50% lower than maternal levels or less. This isn't a deficiency in the motherâ€”it's a characteristic of placental physiology.

### 2. Low Concentration in Breast Milk

Breast milk contains relatively low levels of vitamin K (1â€“4 mcg/L), especially in the first days postpartum. Colostrum has slightly higher levels, but not enough to rapidly replenish newborn stores. Formula is supplemented with vitamin K and provides higher levels.

**Important clarification:** This doesn't mean breast milk is inadequate. Breast milk provides optimal nutrition overall, but vitamin K is one nutrient present in lower concentrationsâ€”a known physiological reality that prophylaxis addresses.

### 3. Sterile Gut at Birth

Newborns are born with a sterile gastrointestinal tract. The gut bacteria that synthesize vitamin K2 in older children and adults haven't yet colonized. It takes weeks to months for bacterial populations to establish and contribute meaningfully to vitamin K production.

### 4. Immature Liver Function

The newborn liver is still maturing. Even when vitamin K is available, the efficiency of clotting factor synthesis is lower in the first weeks of life.

**The combined result:** Newborns have vitamin K stores that are approximately 50% of adult levels at birth, and these stores deplete rapidly without supplementation.

---

## Vitamin K Deficiency Bleeding (VKDB): Types and Timing

VKDB is categorized by timing of onset, with distinct risk profiles and presentations:

### Early VKDB (0â€“24 Hours)

**Timing:** First 24 hours of life

**Incidence:** Rare (0.25â€“1.7% of at-risk infants)

**Risk factors:**

- Maternal medications that interfere with vitamin K metabolism (anticonvulsants like phenytoin, phenobarbital; some antibiotics; warfarin; antitubercular drugs)

**Presentation:** Often severe bleeding, including intracranial hemorrhage, cephalohematoma, gastrointestinal bleeding

**Prevention:** Vitamin K shot at birth provides protection, though early VKDB is primarily driven by maternal medication exposure

### Classic VKDB (1â€“7 Days)

**Timing:** Days 1â€“7 of life

**Incidence without prophylaxis:** 0.25â€“1.7% (approximately 1 in 60â€“200 births)

**Presentation:**

- Bleeding from umbilical stump
- Gastrointestinal bleeding (bloody or black stools)
- Excessive bruising
- Bleeding from nose or puncture sites
- Rarely, intracranial hemorrhage

**Prevention:** Virtually eliminated by vitamin K prophylaxis at birth. When the shot became standard practice, classic VKDB incidence dropped dramatically.

### Late VKDB (2 Weeksâ€“6 Months)

**Timing:** 2 weeks to 6 months (peak incidence: 3â€“8 weeks)

**Incidence without prophylaxis:** 4.4â€“10.5 per 100,000 births among exclusively breastfed infants without vitamin K prophylaxis

**Incidence with IM vitamin K shot:** Extremely rare (approximately 0.25 per 100,000)

**Risk factors:**

- No vitamin K prophylaxis at birth
- Exclusive breastfeeding (lower vitamin K in breast milk)
- Malabsorption disorders (cholestatic liver disease, biliary atresia, cystic fibrosis, celiac disease, chronic diarrhea)

**Presentation:**

- Often presents with sudden, severe bleeding
- **30â€“50% involve intracranial hemorrhage**â€”this is the most feared complication
- Other sites: gastrointestinal, skin (bruising), injection sites

**Why late VKDB is particularly dangerous:**
Unlike classic VKDB (which often presents with visible bleeding like umbilical or GI bleeding), late VKDB frequently presents with intracranial hemorrhage as the first sign. By the time symptoms appear (poor feeding, lethargy, irritability, seizures, bulging fontanelle), brain injury may already be significant.

---

## Neurological Consequences: Why the Brain Is at Risk

As a neurology NP, this is where the stakes become clear. VKDB doesn't just cause bruisingâ€”it causes bleeding in critical locations.

### Intracranial Hemorrhage in VKDB

**Incidence:** 30â€“50% of late VKDB cases involve intracranial hemorrhage (ICH)

**Types of bleeding:**

- Subdural hemorrhage (bleeding between dura and brain)
- Subarachnoid hemorrhage (bleeding around brain surface)
- Intraparenchymal hemorrhage (bleeding within brain tissue)

### Neurological Outcomes

When bleeding occurs in the brain during the first months of lifeâ€”a period of explosive neural developmentâ€”the consequences can be severe:

**Acute complications:**

- Seizures
- Increased intracranial pressure
- Herniation (brain tissue shifts due to pressure, potentially fatal)
- Death (mortality rate for VKDB-related ICH: 10â€“30%)

**Long-term outcomes in survivors:**

- **Approximately 50% of infants with VKDB-related ICH have permanent neurological disability**
- Cerebral palsy
- Developmental delays
- Seizure disorders
- Intellectual disability
- Vision or hearing impairment

**Clinical Insight:**
I evaluate children with cerebral palsy and developmental disabilities in my practice. When I take a detailed birth history and discover vitamin K was declined and bleeding occurred in the neonatal period, I see a preventable injury. A single interventionâ€”administered once, at birthâ€”would have changed that child's lifelong trajectory. The regret parents express in these situations is profound, and it reinforces why I approach this topic with candor rather than reassurance that "everything will be fine either way."

### Why the Developing Brain Is Vulnerable

The infant brain is uniquely susceptible to bleeding complications:

- **High metabolic demand:** The brain requires significant blood flow; disruption has immediate consequences
- **Ongoing critical development:** Bleeding disrupts synaptogenesis, myelination, and structural development
- **Limited compensatory capacity:** Unlike older children and adults, infants have less reserve; small hemorrhages can have disproportionate impact
- **Fragile vasculature:** Developing blood vessels are more prone to rupture with trauma or clotting dysfunction

---

## The Vitamin K Shot: Dosing and Safety

### Standard Prophylaxis Protocol

**Dose:** 0.5â€“1 mg vitamin K1 (phytonadione) intramuscularly

**Timing:** Within the first hour after birth (ideally) or before hospital discharge

**Route:** Intramuscular injection, typically into the anterolateral thigh

**Formulation:** Aqueous solution (NOT the old mixed micellar formulation, which was associated with concerns in early studies)

### How It Works

The intramuscular injection creates a depot of vitamin K in muscle tissue. Vitamin K is released slowly over weeks to months, providing:

- Immediate elevation of vitamin K levels (within hours)
- Sustained protective levels throughout the highest-risk period for late VKDB (first 3â€“6 months)

### Safety Profile

The vitamin K shot has been administered to millions of newborns worldwide since the 1960s.

**Known side effects:**

- Pain and crying at injection (brief, resolves within minutes)
- Occasional small bruise or nodule at injection site

**No evidence of:**

- Allergic reactions (extremely rare)
- Long-term adverse effects
- Increased cancer risk (addressed below)

### Addressing the Cancer Concern

In 1992, a single study from the UK suggested a possible association between IM vitamin K and childhood leukemia. This finding caused significant parental concern.

**Subsequent evidence:**

- Multiple large studies (including meta-analyses) have found **no association** between IM vitamin K and childhood cancer
- The original study had methodological limitations and has not been replicated
- Major medical organizations (AAP, WHO, CDC) reviewed the evidence and affirmed that IM vitamin K is safe

**Current consensus:** There is no credible evidence linking vitamin K prophylaxis to cancer risk.

---

## Intramuscular vs. Oral: Comparing Effectiveness

Some parents ask about oral vitamin K as an alternative to the injection. Let's examine the evidence.

### Oral Vitamin K Protocols

Oral protocols vary by country and typically involve:

- Multiple doses (e.g., at birth, 1 week, 4â€“6 weeks)
- Higher total vitamin K compared to single IM dose (to compensate for lower absorption)

**Examples:**

- Netherlands: 1 mg at birth, then daily 25 mcg for 12 weeks
- Denmark: 2 mg at birth, 1 mg at 1 week, 1 mg at 4 weeks

### Efficacy Comparison

**Intramuscular (IM) vitamin K:**

- **Classic VKDB prevention:** >95% effective (essentially eliminates classic VKDB)
- **Late VKDB prevention:** Reduces incidence to approximately 0.25 per 100,000 (extremely rare)

**Oral vitamin K (multiple-dose regimens):**

- **Classic VKDB prevention:** Effective when first dose is given at birth
- **Late VKDB prevention:** Reduces incidence to approximately 1.2â€“4.4 per 100,000

**The difference:** Oral vitamin K reduces late VKDB risk compared to no prophylaxis, but **IM vitamin K is significantly more effective** (approximately 5â€“20 times lower late VKDB incidence).

### Why IM Is More Effective

Several factors explain the superior efficacy of IM administration:

1. **Guaranteed delivery:** IM injection ensures the dose is received. Oral doses can be spit up or vomited.

2. **Absorption variability:** Oral vitamin K absorption varies based on gut function, fat digestion, and bile productionâ€”all immature in newborns. Some infants (especially those with undiagnosed cholestatic disorders) absorb very little oral vitamin K.

3. **Sustained release:** IM creates a depot that releases vitamin K over weeks to months. Oral dosing relies on repeated administration and sustained absorption.

4. **Compliance:** Multi-dose oral regimens require parents to remember subsequent doses and return for administration. Missed doses eliminate protection.

5. **Malabsorption disorders:** Infants with undiagnosed conditions affecting fat absorption (biliary atresia, cholestatic jaundice) won't absorb oral vitamin K adequatelyâ€”these are precisely the infants at highest risk for late VKDB.

**Clinical Insight:**
Late VKDB cases I'm aware of through case reports and clinical networks disproportionately involve either (1) no vitamin K prophylaxis or (2) oral vitamin K in infants with undiagnosed malabsorption. The infants who develop ICH despite "vitamin K supplementation" often had cholestatic jaundice or other conditions preventing oral absorption. IM vitamin K bypasses this vulnerability.

---

## Common Concerns About the Vitamin K Shot

Let's address concerns parents raise, using evidence rather than dismissiveness.

### "It's not naturalâ€”babies are born this way for a reason"

**The physiological reality:** Newborn vitamin K deficiency is a consequence of mammalian placental physiology and gut sterility at birthâ€”not an intentional evolutionary design conferring benefit.

Historically, before vitamin K prophylaxis, infant bleeding was recognized as a medical problem (described as "hemorrhagic disease of the newborn" as early as the 1800s). Natural doesn't always mean optimal. Humans evolved in environments with different selection pressures; modern medical intervention addresses vulnerabilities that historically resulted in infant mortality.

**The evidence-based perspective:** Vitamin K prophylaxis is an intervention that corrects a known physiological vulnerability. Just as we provide warmth, nutrition, and infection screening at birth, we address vitamin K deficiency because we canâ€”and because the consequences of not doing so can be catastrophic.

### "The dose is too high for a baby's body"

**The pharmacology:** The 1 mg IM dose is designed to create a sustained depot. While it's proportionally higher than adult daily requirements, the slow release over weeks to months means circulating levels remain in a safe, physiological rangeâ€”not a toxic bolus.

**Safety data:** Decades of use in millions of newborns demonstrate no adverse effects from the dose magnitude. Vitamin K is fat-soluble but has low toxicity; excess is not associated with harm in the doses used for prophylaxis.

### "I'm breastfeeding, so my baby will get vitamin K from milk"

**The evidence:** Breast milk contains 1â€“4 mcg/L of vitamin Kâ€”inadequate to rapidly replenish newborn stores or provide sustained protection throughout the high-risk period for late VKDB.

Exclusively breastfed infants without vitamin K prophylaxis have the highest incidence of late VKDB. This isn't a failure of breastfeedingâ€”it's a known characteristic of human milk. Formula is supplemented with vitamin K specifically to address this.

**The clinical reality:** Breast milk is optimal nutrition overall, but vitamin K is one nutrient where supplementation at birth is necessary to prevent a rare but serious outcome.

### "I'll just do oral vitamin K instead"

**The practicality:** If oral vitamin K is available and you prefer it, multiple doses are better than none. However, understand the data: oral vitamin K is less effective than IM, particularly for late VKDB.

**The compliance challenge:** Multi-dose regimens require remembering and administering subsequent doses. In countries using oral protocols, late VKDB still occurs due to missed doses or malabsorption.

**The malabsorption risk:** Infants with cholestatic jaundice, biliary atresia, or other fat malabsorption disorders (often undiagnosed at birth) cannot adequately absorb oral vitamin K. These are the highest-risk infants, and oral administration fails precisely when it's needed most.

**The risk-benefit assessment:** IM vitamin K provides superior, sustained protection with a single intervention. Oral vitamin K requires multiple doses, depends on absorption, and leaves a residual risk gap.

---

## What Happens If You Decline

You have the right to decline vitamin K prophylaxis for your newborn. Here's what that decision means:

### The Baseline Risk

**Without vitamin K prophylaxis:**

- Classic VKDB risk: 0.25â€“1.7% (approximately 1 in 60â€“200 births)
- Late VKDB risk (exclusively breastfed): 4.4â€“10.5 per 100,000

**With IM vitamin K:**

- Classic VKDB risk: Essentially eliminated
- Late VKDB risk: ~0.25 per 100,000

**Risk reduction:** IM vitamin K reduces late VKDB risk by approximately 95â€“98% compared to no prophylaxis.

### The Numerical Reality

These percentages represent real infants. In the United States, approximately 3.6 million babies are born annually. If all declined vitamin K:

- Approximately 160â€“380 infants would develop late VKDB per year
- 50â€“190 of those would involve intracranial hemorrhage
- 25â€“95 would die or have permanent neurological disability

Because >95% of U.S. infants receive vitamin K, we see only a small number of VKDB cases annuallyâ€”most in infants whose parents declined.

### What to Monitor If You Decline

If you choose not to give vitamin K, vigilance is essential. Watch for signs of bleeding, especially in the first 6 months:

**Warning signs of VKDB:**

- Unusual bruising (without clear trauma)
- Bleeding from nose, umbilical stump, or circumcision site that doesn't stop
- Blood in stool (red or black, tarry stools)
- Blood in vomit
- Excessive sleepiness or difficulty waking
- Irritability, high-pitched crying
- Poor feeding
- Bulging fontanelle (soft spot)
- Seizures

**If any of these occur, seek immediate emergency care.** VKDB can progress rapidly, and intracranial hemorrhage is a medical emergency.

### Special Considerations

**Higher risk if:**

- Exclusively breastfeeding (lower vitamin K in milk)
- Mother taking medications that interfere with vitamin K (anticonvulsants, some antibiotics)
- Prolonged or difficult delivery (increased bleeding risk)
- Any signs of jaundice or liver dysfunction (malabsorption risk)

**Discuss with your pediatrician** if any of these apply. For high-risk infants, vitamin K prophylaxis becomes even more critical.

---

## Key Takeaways

- âœ“ **Newborns are born with low vitamin K stores** due to poor placental transfer, low breast milk concentration, sterile gut, and immature liver function

- âœ“ **Vitamin K Deficiency Bleeding (VKDB) is rare but serious**â€”30â€“50% of late VKDB cases involve intracranial hemorrhage, with high rates of death or permanent disability

- âœ“ **IM vitamin K at birth is highly effective**â€”reduces late VKDB risk by approximately 95â€“98% with a single dose

- âœ“ **Oral vitamin K is less effective than IM**â€”provides some protection but leaves a residual risk gap, especially in infants with malabsorption disorders

- âœ“ **The IM dose is safe**â€”decades of evidence show no association with cancer or other long-term adverse effects

- âœ“ **The infant brain is uniquely vulnerable to bleeding**â€”hemorrhage during the first months disrupts critical development and can cause lifelong neurological impairment

- âœ“ **This is a low-burden, high-impact intervention**â€”a single injection administered once prevents a rare but potentially catastrophic outcome

- âœ“ **If you decline, vigilance is essential**â€”know the warning signs and seek immediate care for any bleeding or neurological symptoms

---

## Frequently Asked Questions

**Q: Can I just give my baby vitamin K-rich foods once they start solids?**

A: The highest risk period for late VKDB is 2 weeks to 6 months, with peak incidence at 3â€“8 weeksâ€”well before most infants start solid foods (typically around 6 months). Additionally, newborns and young infants cannot effectively absorb and utilize dietary vitamin K due to immature gut and liver function. By the time solid foods are introduced, the critical risk window has passed, but the infant has been vulnerable throughout.

**Q: If vitamin K deficiency is natural, why didn't babies historically have more bleeding problems?**

A: They did. Hemorrhagic disease of the newborn was documented in medical literature long before vitamin K was identified as the cause. Infant mortality was higher historically, and some deaths attributed to other causes may have been VKDB. Additionally, late VKDB incidence (even without prophylaxis) is still relatively low (approximately 1 in 10,000â€“20,000 exclusively breastfed infants)â€”serious but uncommon enough that individual communities might not have recognized the pattern.

**Q: Does the vitamin K shot contain harmful additives or preservatives?**

A: The current formulation of vitamin K1 (phytonadione) used in the U.S. contains vitamin K, polysorbate 80, dextrose, and benzyl alcohol. These ingredients are present in small amounts and have established safety profiles in neonates. The formulation has been used safely in millions of newborns. If you have concerns about specific ingredients, discuss them with your pediatrician, but understand that the excipients are necessary for stability and absorption and are used in many pediatric medications.

**Q: Can I wait and give vitamin K later if my baby shows signs of deficiency?**

A: Late VKDB often presents with sudden, severe bleedingâ€”frequently intracranial hemorrhage as the first sign. By the time symptoms are apparent, brain injury may already be significant. VKDB is a poor candidate for "wait and see" because the first manifestation can be catastrophic. Prevention is far superior to treatment after bleeding has begun.

**Q: Is vitamin K prophylaxis just a profit-driven recommendation by pharmaceutical companies?**

A: Vitamin K is a generic medication that costs approximately $2â€“10 per dose. There is no meaningful profit motive driving this recommendation. The practice is supported by decades of evidence and endorsed globally by pediatric and public health organizations because it prevents a serious, measurable harm. Countries with universal healthcare (where profit motive is absent) uniformly recommend vitamin K prophylaxis.

**Q: My first child didn't get vitamin K and was fine. Why should I give it to this baby?**

A: VKDB incidenceâ€”even without prophylaxisâ€”is relatively low (classic VKDB: ~1 in 60â€“200; late VKDB: ~1 in 10,000â€“20,000 for breastfed infants). Most infants without vitamin K will not develop VKDB, but some will. The issue is that you cannot predict which infant will bleed. It's similar to car seat use: most unrestrained children won't be in a crash, but we use car seats for every child because we can't predict which one will need the protection. One child's outcome doesn't predict another's risk.

**Q: What if my baby has jaundice? Does that change the vitamin K recommendation?**

A: Yesâ€”jaundice, especially if prolonged or severe, may indicate cholestatic liver disease or biliary obstruction. These conditions impair fat absorption, meaning oral vitamin K won't be absorbed effectively. Infants with cholestasis are at **significantly higher risk** for VKDB and absolutely require IM vitamin K (or IV if IM is not possible). If your baby develops jaundice beyond the first week or has pale stools and dark urine, contact your pediatrician immediately.

**Q: Can vitamin K be given IV instead of IM?**

A: IV vitamin K can be used in certain clinical situations (e.g., when IM injection is contraindicated due to bleeding disorder or thrombocytopenia), but it doesn't provide the sustained depot effect of IM administration. IV dosing may require repeated administration. IM remains the standard route for newborn prophylaxis because of the sustained protection it provides.

---

## Related Resources

**Quick Help:**

- ðŸš¨ [Newborn bleeding: When to seek emergency care](/quick-help/newborn-bleeding)
- ðŸš¨ [Jaundice in newborns: Warning signs](/quick-help/newborn-jaundice)

**How-To Guides:**

- ðŸŽ¯ [Newborn care basics: First 48 hours](/guides/newborn/first-48-hours)
- ðŸŽ¯ [Breastfeeding essentials: What to expect](/guides/feeding/breastfeeding-basics)

**Further Reading:**

- ðŸ“š [Understanding newborn screening: What tests and why](/blog/newborn-screening-guide)
- ðŸ“š [Developmental milestones: A neurology NP's guide](/blog/developmental-milestones-guide)

---

## References & Citations

1. American Academy of Pediatrics Committee on Fetus and Newborn. (2003). "Controversies Concerning Vitamin K and the Newborn." Pediatrics, 112(1), 191-192.

2. Schulte, R., Jordan, L.C., Morad, A., et al. (2014). "Rise in Late Onset Vitamin K Deficiency Bleeding in Young Infants Because of Omission or Refusal of Prophylaxis at Birth." Pediatric Neurology, 50(6), 564-568.

3. Mihatsch, W.A., Braegger, C., Bronsky, J., et al. (2016). "ESPGHAN Committee on Nutrition Position Paper: Vitamin K in the Newborn." Journal of Pediatric Gastroenterology and Nutrition, 63(3), 430-441.

4. Busfield, A., Samuel, R., McNinch, A., Tripp, J.H. (2007). "Vitamin K Deficiency Bleeding After NICE Guidance and Withdrawal of Konakion Neonatal: British Paediatric Surveillance Unit study, 2006-2008." Archives of Disease in Childhood, 98(1), 41-47.

5. Passmore, S.J., et al. (1998). "Case-Control Studies of Relation Between Childhood Cancer and Neonatal Vitamin K Administration: Retrospective Case-Control Study." BMJ, 316(7126), 178-184.

6. Ross, J.A., Davies, S.M. (2000). "Vitamin K Prophylaxis and Childhood Cancer." Medical and Pediatric Oncology, 34(6), 434-437.

7. Shearer, M.J. (2009). "Vitamin K Deficiency Bleeding (VKDB) in Early Infancy." Blood Reviews, 23(2), 49-59.

8. World Health Organization. (1999). "Vitamin K for Neonates: Policy Guidelines." WHO Department of Child and Adolescent Health and Development.

9. Lippi, G., Franchini, M. (2011). "Vitamin K in Neonates: Facts and Myths." Blood Transfusion, 9(1), 4-9.

10. Victora, C.G., et al. (2016). "Breastfeeding in the 21st Century: Epidemiology, Mechanisms, and Lifelong Effect." The Lancet, 387(10017), 475-490.

---

## About the Author

**Alisha Blevins, MSN, CPNP-PC, Pediatric Neurology NP**, is a board-certified Pediatric Nurse Practitioner specializing in pediatric neurology with over 8 years of clinical experience. In her practice, she evaluates and treats infants and children with neurological and developmental concerns, including those with bleeding-related brain injuries.

Understanding that parents receive conflicting information about newborn interventions, she approaches vitamin K prophylaxis with the same evidence-based candor she brings to all clinical decisions: acknowledging the rarity of VKDB while recognizing the severity when it occurs, and presenting the data that informs standard-of-care recommendations.

---

**Medical Review:** [Your Name], MSN, CPNP-AC, Pediatric Neurology NP
**Published:** January 22, 2025
**Last Updated:** January 22, 2025

**Medical Disclaimer:** This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your pediatrician or other qualified health provider with questions about your newborn's care and medical interventions.
